DSIP Mechanisms (What We Actually Know) Animal models show the following: Dose-dependent antinociceptive effects (pain reduction) Naloxone blockade, indicating opioid receptor involvement The effects on human subjects appear to be broader: Stress modulation Neurotransmitter regulation Possible circadian interaction The exact receptor targets remain undefined as of now, which means the optimal subcutaneous dose of DSIP has not been scientifically established
Concentrated formula ensures optimal dosage for maximum effectiveness
The compound creates an opportunity for fat loss
Recruitment of stromal cells, immune cells and progenitors is another potential mechanism for resistance to anti-angiogenic therapy

Angiogenic Pathway Activation Multiple components contribute to blood vessel formation through distinct but complementary mechanisms: BPC-157 upregulates VEGFR2 expression and enhances endothelial cell proliferation TB-500 promotes endothelial cell migration and tube formation GHK-Cu stimulates angiogenic growth factor expression and vessel maturation Combined effects result in improved tissue vascularization and nutrient delivery Anti-Inflammatory Pathway Modulation The blend provides comprehensive inflammation control through multiple targets: BPC-157 modulates nitric oxide synthesis and reduces pro-inflammatory cytokines TB-500 influences inflammatory mediator expression through cytoskeletal mechanisms GHK-Cu reduces oxidative stress and modulates immune cell function Coordinated effects help resolve inflammation while promoting healing Synergistic Advantage: GLOW Blends multi-pathway approach enables simultaneous activation of cellular migration, matrix synthesis, angiogenesis, and inflammation control

Reduce CJC-1295 dose by 2550% rather than discontinuing entirelywater retention correlates more strongly with CJC-1295 than MK-677 in combination protocols